Bacillus Calmette-Guerin (BCG) is commonly and safely used as intravesical instillation to treat bladder cancer. Adverse effects are widely described in case report and series with a broad range of clinical presentations known as “BCGitis”. Moreover, microbiological identification is often inconclusive leading to diagnostic uncertainty and no standardisation of definitions is available. We retrospectively collected all cases of BCGitis (n=19) after BCG intravesical administration occurred in 2 major Italian hospitals in the last 10 years. Median age was 71.8 years and among comorbidities hypertension affected 60% of patients. The delay in the onset of symptoms was < one week and an inverse correlation was observed between the number of instillations and the time to the onset of symptoms. Moreover, a febrile presentation was the commonest clinical symptom (85%) and an interstitial or micronodular pattern at chest X-ray or CT scan was found positive in about 70% and 90% of cases, respectively. Larger cohorts are needed in order to inform clinically relevant algorythms for this uncommon disease.

De Benedetto, I., Barco, A., Rossi, M., Lapadula, G., Lupia, T., Bonfanti, P., et al. (2022). BCGitis after Bacille Calmette-Guerin intravesical administration from two referral centers: clinical characteristics and risk factors. LE INFEZIONI IN MEDICINA, 30(2), 242-246 [10.53854/liim-3002-9].

BCGitis after Bacille Calmette-Guerin intravesical administration from two referral centers: clinical characteristics and risk factors

Lapadula G.;Bonfanti P.;
2022

Abstract

Bacillus Calmette-Guerin (BCG) is commonly and safely used as intravesical instillation to treat bladder cancer. Adverse effects are widely described in case report and series with a broad range of clinical presentations known as “BCGitis”. Moreover, microbiological identification is often inconclusive leading to diagnostic uncertainty and no standardisation of definitions is available. We retrospectively collected all cases of BCGitis (n=19) after BCG intravesical administration occurred in 2 major Italian hospitals in the last 10 years. Median age was 71.8 years and among comorbidities hypertension affected 60% of patients. The delay in the onset of symptoms was < one week and an inverse correlation was observed between the number of instillations and the time to the onset of symptoms. Moreover, a febrile presentation was the commonest clinical symptom (85%) and an interstitial or micronodular pattern at chest X-ray or CT scan was found positive in about 70% and 90% of cases, respectively. Larger cohorts are needed in order to inform clinically relevant algorythms for this uncommon disease.
Articolo in rivista - Articolo scientifico
BCG; BCGitis; bladder; epidemiology; instillation;
English
2022
30
2
242
246
none
De Benedetto, I., Barco, A., Rossi, M., Lapadula, G., Lupia, T., Bonfanti, P., et al. (2022). BCGitis after Bacille Calmette-Guerin intravesical administration from two referral centers: clinical characteristics and risk factors. LE INFEZIONI IN MEDICINA, 30(2), 242-246 [10.53854/liim-3002-9].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/392748
Citazioni
  • Scopus 2
  • ???jsp.display-item.citation.isi??? ND
Social impact